Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Watson Signs Definitive Agreement To Acquire Arrow Group
Watson Pharmaceuticals has entered into a definitive agreement to acquire Arrow Group for $1.75 billion in cash and stock. The combination of Watson and Arrow will result in
Watson Pharmaceuticals has entered into a definitive agreement to acquire Arrow Group for $1.75 billion in cash and stock. The combination of Watson and Arrow will result in
Epeius’ Rexin-G has been granted FDA’ fast track designation, for use as a second-line treatment for advanced or metastatic pancreatic cancer. The designation is granted following a critical
Cepheid has released its improved Xpert BCR-ABL Monitor test, to be marketed as a CE IVD product under the European Directive. It is intended to aid European clinicians
Antigenics has announced the launch of phase-III trial for malaria vaccine, RTS,S by GlaxoSmithKline, which contains Antigenics’ QS-21 Stimulon adjuvant. Phase-II malaria studies showed that, over an eight-month
Access has signed evaluation agreements with two biopharmaceutical companies, for its Cobalamin oral drug delivery technology. Cobalamin technology utilizes the body’s natural vitamin B12 oral uptake mechanism to
Global Alliance for TB and Tibotec have enterned into a partnership to accelerate the discovery and development of new drugs for tuberculosis (TB). The two organizations will share
Xanodyne has received approval from the FDA for Zipsor (diclofenac potassium) Liquid Filled Capsules, to treat mild-to-moderate acute pain in adults. The recommended daily dose of diclofenac potassium
Canada-based Neuromed has sold the US rights of its investigational drug candidate, Exalgo (hydromorphone HCl), an extended-release tablets, to Covidien’s subsidiary, Mallinckrodt. Neuromed has received a one-time upfront
Xcellerex has announced that Crucell is acquiring a FlexFactory bioproduction line and multiple XDR single-use bioreactors, to expand the manufacturing capabilities. The project will deliver new, validated clinical
Clavis has announced positive final results from a phase-II trial of its novel investigational cancer drug, elacytarabine (CP-4055), in patients with late-stage acute myeloid leukaemia (AML). Elacytarabine is